UBC global review confirms mRNA vaccines are safe and effective

A sweeping global review led by researchers at the University of British Columbia has found that mRNA vaccines — now administered billions of times worldwide — are safe and highly effective at preventing infectious diseases like COVID-19, and have potential applications for a range of other diseases, including influenza, RSV, cancer and autoimmune disorders.

The review details the full lifecycle of mRNA technology, from initial design and manufacturing processes to post-administration monitoring. Researchers emphasize that the platform is being adapted for a broad range of medical applications, including preventative vaccines for influenza and respiratory syncytial virus (RSV), as well as personalized therapies for oncology and autoimmune disorders.

Media additions

Mechanism and Safety Profile

The report clarifies how mRNA vaccines function by providing temporary instructions that allow human cells to produce a harmless piece of a virus, training the immune system to respond. The mRNA and the lipid nanoparticles used for delivery are broken down and cleared by the body shortly after administration. Experts highlight that this process does not alter a person’s DNA, effectively countering persistent public misconceptions. While the study confirms a high safety profile, it acknowledges that, like all medical interventions, side effects can occur. Rare instances of myocarditis, which occurs more frequently in younger males, have been observed. However, the report notes that the protection afforded by these vaccines against severe illness, hospitalization, and death consistently outweighs these rare risks.

Beyond infectious diseases, the review notes that mRNA technology allows for the rapid development of vaccines in response to emerging pathogens. Researchers point to the platform's versatility, suggesting it could eventually be tailored to target specific cancer antigens or modulate autoimmune reactions, representing a significant shift toward personalized medicine.

Global Context and Future Outlook

Researchers underscore that sustained investment is required to improve global manufacturing capacity, particularly in low- and middle-income countries, to ensure equitable access. Addressing vaccine hesitancy is identified as a priority, with authors suggesting that concerns should be met with transparent communication and accessible, evidence-based data rather than dismissal.

As the scientific community shifts focus toward the next generation of mRNA therapies, the researchers stress that the goal is to provide a unified resource to empower informed decision-making. The review serves as a guide for what lies ahead, as the same underlying platform used to combat the COVID-19 pandemic is repurposed for a spectrum of future medical treatments.

"After billions of doses, we now have an extraordinary amount of scientific evidence,” said lead author Dr. Anna Blakney, assistant professor at UBC’s Michael Smith Laboratories and School of Biomedical Engineering. “This review affirms that mRNA vaccines are a safe and highly effective platform, supported by rigorous testing and real-world monitoring. It provides an evidence-based foundation as this technology continues to expand into new areas of medicine."

“With any new vaccine or medicine, it is important that we clearly and transparently communicate the safety data and rigorous testing that supports their use,” said co-author Dr. Manish Sadarangani, professor of pediatrics at UBC and director of the Vaccine Evaluation Center at BC Children’s Hospital Research Institute. “This is essential to building public trust, countering misinformation and supporting informed decisions about vaccination.”